Stefania De Pascalis
Overview
Explore the profile of Stefania De Pascalis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
221
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coppola N, Alessio L, De Pascalis S, Macera M, Di Caprio G, Messina V, et al.
Infect Dis Poverty
. 2024 May;
13(1):39.
PMID: 38802954
Background: Migrants, mainly undocumented and low-income refugees, are at high risk of hepatitis C virus (HCV) infection, but are a difficult-to-reach and to-treat population. The aim of the study was...
2.
Monari C, Molinari D, Cornelli A, Alessio L, Coppolino F, Barbareschi C, et al.
Infect Dis Rep
. 2023 Sep;
15(5):494-503.
PMID: 37736996
Multivalvular endocarditis (MVE) is an uncommon infection that mostly involves mitral and aortic valves, and it is related to a higher risk of congestive heart failure and a higher mortality....
3.
Pisaturo M, Alessio L, De Pascalis S, Messina V, Onorato L, Coppola N
Gastroenterology
. 2023 Sep;
166(1):191-193.e2.
PMID: 37690773
No abstract available.
4.
Altieri M, Melisi R, Conte M, Capuano R, Donnarumma G, Grimaldi E, et al.
Neurol Sci
. 2023 Jul;
44(11):4107-4110.
PMID: 37498399
Background: Evusheld (EVS) was authorized by FDA and EMA as pre-exposure prophylaxis (PrEP) in people at high risk of severe Covid-19 outcomes, including people with Multiple Sclerosis (pwMS) on B-cell...
5.
Nevola R, Feola G, Ruocco R, Russo A, Villani A, Fusco R, et al.
Int J Infect Dis
. 2023 Mar;
131:155-161.
PMID: 36944382
Objectives: There is a scarcity of data on the outcomes and predictors of therapeutic failure of monoclonal antibodies (mAbs) in frail patients with COVID-19. Methods: Prospective study including consecutive COVID-19...
6.
Marcacci G, Coppola N, Madonna E, Becchimanzi C, De Pascalis S, DOvidio S, et al.
Infect Agent Cancer
. 2022 Aug;
17(1):41.
PMID: 35922822
Background: To date, there is no information on the safety and efficacy of the novel anti-sarbecoviruses monoclonal antibody sotrovimab administered, as a post-exposure prophylactic measure, during the aplastic phase of...
7.
Sagnelli C, Montella L, Grimaldi P, Pisaturo M, Alessio L, De Pascalis S, et al.
Pathogens
. 2022 Jul;
11(7).
PMID: 35890060
Universal hepatitis B virus (HBV) vaccination has been applied for years in most countries, but HBV infection remains an unresolved public health problem worldwide, with over one-third of the world's...
8.
Maggi P, Calo F, Messina V, Stornaiuolo G, Stanzione M, Rinaldi L, et al.
PLoS One
. 2022 Mar;
17(3):e0265178.
PMID: 35294954
Background: Cardiovascular disease (CVD) is a major cause of morbidity and mortality after liver transplantation, mostly in patients transplanted for nonalcoholic steatohepatitis, obesity and diabetes. Few data exist on cardiovascular...
9.
Scotto R, Buonomo A, De Pascalis S, Nerilli M, Pinchera B, Staiano L, et al.
Expert Rev Gastroenterol Hepatol
. 2021 Feb;
15(9):1057-1063.
PMID: 33573411
Background: Second generation direct acting antivirals (DAAs) drastically changed the landscape of chronic HCV (CHCV). Aim of this paper was to assess the effectiveness of DAAs, also looking at the...
10.
Calo F, Russo A, Camaioni C, De Pascalis S, Coppola N
Infect Dis Poverty
. 2020 Oct;
9(1):139.
PMID: 33028400
Background: Health workers (HWs) are at increased risk for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection and a possible source of nosocomial transmission clusters. Despite the increased risk, the best surveillance...